Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Easterbrook

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Virology|October 19, 2007
WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infectionR Alvarez, J Reading, D F L King, et al.
HIV Medicine|April 28, 2007
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003W Stöhr, Dt Dunn, K Porter, et al.
AIDS (London, England)|November 5, 1999
Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering GroupE J Beck, S Mandalia, I Williams, et al.
Journal of Viral Hepatitis|October 21, 2009
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomesJ Turner, L Bansi, R Gilson, et al.
HIV Medicine|November 9, 2010
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late startersL Waters, M Fisher, J Anderson, et al.
Pharmacoeconomics|May 27, 1999
The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on CostsE J Beck, K Tolley, A Power, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
HIV Medicine|February 12, 2010
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populationsL Bansi, C Sabin, V Delpech, et al.
The Journal of Experimental Medicine|July 6, 2000
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic functionV Appay, D F Nixon, S M Donahoe, et al.
HIV Medicine|May 17, 2011
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) studyR A Hughes, J A C Sterne, J Walsh, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Virology|October 19, 2007
WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infectionR Alvarez, J Reading, D F L King, et al.
HIV Medicine|April 28, 2007
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003W Stöhr, Dt Dunn, K Porter, et al.
AIDS (London, England)|November 5, 1999
Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering GroupE J Beck, S Mandalia, I Williams, et al.
Journal of Viral Hepatitis|October 21, 2009
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomesJ Turner, L Bansi, R Gilson, et al.
HIV Medicine|November 9, 2010
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late startersL Waters, M Fisher, J Anderson, et al.
Pharmacoeconomics|May 27, 1999
The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on CostsE J Beck, K Tolley, A Power, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
HIV Medicine|February 12, 2010
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populationsL Bansi, C Sabin, V Delpech, et al.
The Journal of Experimental Medicine|July 6, 2000
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic functionV Appay, D F Nixon, S M Donahoe, et al.
HIV Medicine|May 17, 2011
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) studyR A Hughes, J A C Sterne, J Walsh, et al.
Pageof 5